# HDAC Inhibitor Combination With Chemoimmunotherapy in the Neoadjuvant Treatment of pMMR Locally Advanced Colon Cancer

Source: https://onco.cc/trials/nct06709885/  
OnCo record `nct06709885` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of tucidinostat (chidamide), tislelizumab and cAPOX (capecitabine, oxaliplatin) in colorectal cancer, run by Daping Hospital and the Research Institute of Surgery of the Third Military Medical University, now recruiting.

## Summary

HDAC Inhibitor Combination With Chemoimmunotherapy in the Neoadjuvant Treatment of pMMR Locally Advanced Colon Cancer is a phase 2, randomised interventional study registered as NCT06709885 by Daping Hospital and the Research Institute of Surgery of the Third Military Medical University, with a registry enrolment figure of 100 participants, started 2024-10-15 and due to reach its primary completion in 2025-09-30. Interventions recorded: Chidamide + Tislelizumab + chemotherapy (CapeOX ); CapeOX. Conditions listed: Colon Adenocarcinoma. Primary outcome: pCR. Colorectal eligibility wording from the registry: "Patients with colon cancer who are assessed by abdominal contrast-enhanced CT/abdominopelvic MRI as high-risk T3 (tumor destroys muscle wall and extends to pericolonic fat, protruding more than 5 mm into adjacent mesenteric fat) or T4 (tumor penetrates the visceral peritoneal surface or directly inv". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT06709885
- Phase: 2
- Setting: HDAC Inhibitor Combination With Immunochemotherapy in the Neoadjuvant Treatment of pMMR Locally Advanced Colon Cancer: A Multicenter, Double-arm, Phase II Randomized Controlled Study
- Sponsor: Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
- Enrolled: 100

## Sources

- ClinicalTrials.gov NCT06709885: https://clinicaltrials.gov/study/NCT06709885

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Platinum agents](https://onco.cc/technologies/platinum/)
- drugs: [CAPOX (capecitabine, oxaliplatin)](https://onco.cc/drugs/capox/), [Tislelizumab](https://onco.cc/drugs/tislelizumab/), [Tucidinostat (chidamide)](https://onco.cc/drugs/tucidinostat/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06709885.json